Stoke Therapeutics (STOK) Research & Development (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Research & Development of $39.7 million for Q1 2026, up 21.41% year-over-year from $32.7 million in Q1 2025, and down 4.85% quarter-over-quarter from $41.7 million in Q4 2025.
Stoke Therapeutics (STOK) Research & Development (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $39.7 million for Q1 2026.
- In Q1 2026, Research & Development rose 21.41% year-over-year to $39.7 million; the TTM figure through Mar 2026 stood at $144.9 million (up 45.74% YoY), while the FY2025 annual figure was $137.9 million, up 54.74% from the prior year.
- Research & Development for Q1 2026 stood at $39.7 million, down from $41.7 million in the prior quarter.
- The five-year high for Research & Development was $41.7 million in Q4 2025, with the low at $18.3 million in Q1 2022.
- The 5-year median for Research & Development is $21.8 million (2023), against an average of $25.1 million.
- The sharpest annual moves came in 2022 and 2023: Research & Development surged 84.7% in 2022, then rose 0.81% in 2023.
- Stoke Therapeutics' Research & Development stood at $21.1 million in 2022, then climbed by 3.41% to $21.8 million in 2023, then rose by 7.55% to $23.4 million in 2024, then soared by 78.01% to $41.7 million in 2025, then fell by 4.85% to $39.7 million in 2026.
- Business Quant data shows STOK's Research & Development at $39.7 million in Q1 2026, $41.7 million in Q4 2025, and $37.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 49.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.50 Mn |
| Mar 31, 2026 | 39.67 Mn |
| Dec 31, 2025 | 41.70 Mn |
| Sep 30, 2025 | 37.70 Mn |
| Jun 30, 2025 | 25.86 Mn |
| Mar 31, 2025 | 32.68 Mn |
| Dec 31, 2024 | 23.42 Mn |
| Sep 30, 2024 | 22.21 Mn |
| Jun 30, 2024 | 21.14 Mn |
| Mar 31, 2024 | 22.37 Mn |
| Dec 31, 2023 | 21.78 Mn |
| Sep 30, 2023 | 20.27 Mn |
| Jun 30, 2023 | 20.55 Mn |
| Mar 31, 2023 | 19.63 Mn |
| Dec 31, 2022 | 21.06 Mn |
| Sep 30, 2022 | 20.11 Mn |
| Jun 30, 2022 | 18.36 Mn |
| Mar 31, 2022 | 18.31 Mn |
| Dec 31, 2021 | 15.80 Mn |
| Sep 30, 2021 | 14.36 Mn |